Sector Gamma AS Lowers Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Sector Gamma AS lowered its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 18.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,712 shares of the medical equipment provider’s stock after selling 6,000 shares during the quarter. Lantheus accounts for 0.8% of Sector Gamma AS’s investment portfolio, making the stock its 29th biggest position. Sector Gamma AS’s holdings in Lantheus were worth $2,300,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its holdings in Lantheus by 2.0% in the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after acquiring an additional 32,551 shares during the last quarter. Massachusetts Financial Services Co. MA acquired a new position in Lantheus in the third quarter valued at $25,955,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Lantheus by 47.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock valued at $1,041,000 after acquiring an additional 3,772 shares during the last quarter. Empirical Asset Management LLC acquired a new position in shares of Lantheus during the fourth quarter worth about $323,000. Finally, Focus Financial Network Inc. acquired a new position in shares of Lantheus during the fourth quarter worth about $292,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on LNTH shares. Truist Financial boosted their price objective on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. The Goldman Sachs Group started coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, JMP Securities restated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $132.86.

Insider Activity at Lantheus

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now directly owns 113,860 shares of the company’s stock, valued at $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 64,109 shares of company stock valued at $6,110,806 over the last three months. 1.50% of the stock is owned by insiders.

Lantheus Stock Performance

NASDAQ:LNTH opened at $98.85 on Friday. Lantheus Holdings, Inc. has a one year low of $57.92 and a one year high of $126.89. The business’s 50-day simple moving average is $92.64 and its 200 day simple moving average is $96.70. The stock has a market cap of $6.77 billion, a price-to-earnings ratio of 16.45 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. On average, equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.